Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00466284
Status:
UNKNOWN
Last Update Posted:
2007-04-27
First Post:
2007-04-25
Brief Title:
Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer
Sponsor:
Grupo Gallego de Cancer de Pulmon
Organization:
Grupo Gallego de Cancer de Pulmon
Study Overview
Official Title:
Phase II Trial of Tarceva Following Concurrent Chemo-Radiotherapy as First Line Therapy in Patients With Unresectable Non-Small Cell Lung Cancer
Status:
UNKNOWN
Status Verified Date:
2007-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A open label non- randomized Phase II trial It is anticipated that approximately 46 patients will be treated
STUDY OBJECTIVES
Primary Objective response rate
Secondary Progression free survival Overall survival and Safety of Tarceva
STUDY OBJECTIVES
Primary Objective response rate
Secondary Progression free survival Overall survival and Safety of Tarceva
Detailed Description:
Study Design Phase II trial open label non-randomized and multicenter
Expected total enrollment 46
Study start January 2006
Study completation January 2008
Expected total enrollment 46
Study start January 2006
Study completation January 2008
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None